TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: VocalizationTechnique During the Second Period of Labor Versus Usual Care for Prevention of Perineal Trauma: Randomized Clinical Trial
Brief Summary: A randomized open-label trial will be conducted to evaluate the effect of vocalization as a perineal protection maneuver during the second period of labor. The study will be carried out in the "Espaço Aconchego" sector of the IMIP, which has a team of obstetrical nurses, medical coordination and physiotherapeutic support. The study population will consist of low-risk parturients, with no prior cesarean indication, admitted to the sector. Those parturients who meet the inclusion criteria, after signing the Informed Consent Term, will be allocated to two groups: Group A (experimental) and Group B (control). Group A will be stimulated to keep the glottis minimally open during spontaneous pushing and to emit sounds when exhaling (vocalization), and Group B will undergo usual routine. Study outcomes will be evaluated by assistents immediately after delivery. After 24 hours of delivery, the conditions of the perineum will be assessed by inspection and palpation of the region,evaluating the presence of edema or other abnormality.


Options:
A: Arm Label: CONTROL; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: VOCALIZATION; Type: EXPERIMENTAL; Interventions: Other: vocalization | Intervention Type: OTHER; Name: vocalization; Assigned to Arm(s): VOCALIZATION
B: Arm Label: Anterior shoulder; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Primary delivery of anterior shoulder | Arm Label: Posterior shoulder; Type: EXPERIMENTAL; Interventions: Procedure: Primary delivery posterior shoulder | Intervention Type: PROCEDURE; Name: Primary delivery of anterior shoulder; Assigned to Arm(s): Anterior shoulder | Intervention Type: PROCEDURE; Name: Primary delivery posterior shoulder; Assigned to Arm(s): Posterior shoulder
C: Arm Label: I; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Ritgens maneuver | Arm Label: II; Type: OTHER; Interventions: Procedure: Standard care (Manual support of the perineum) | Intervention Type: PROCEDURE; Name: Ritgens maneuver; Assigned to Arm(s): I | Intervention Type: PROCEDURE; Name: Standard care (Manual support of the perineum); Assigned to Arm(s): II
D: Arm Label: Perineal device used; Type: OTHER; Interventions: Device: Perineal protection device | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Perineal protection device; Assigned to Arm(s): Perineal device used

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use of a Liquid Supplement Containing 2 Human Milk Oligosaccharides (HMOs) in Preterm Infants: a Double-blind, Randomized, Controlled Trial
Brief Summary: This is a prospective, randomized, double-blind, placebo-controlled trial in preterm infants conducted at least 4 centers in France, consisting of 2 parallel groups. The experimental group will receive a neonatal supplement containing 2 specific HMOs. The control group will receive a placebo neonatal supplement that does not contain any HMOs, but matched to the experimental product in energy content.

This study will include a total of approximately 86 male and female preterm infants born between 27 and 32 weeks' gestational age with birth weight ≤1700 g, who are younger than 7 days of age.

The primary objective of the study is to demonstrate the safety and tolerance of HMOs in preterm infants by monitoring weight gain rates in both of the two randomized groups.


Options:
A: Arm Label: Main Study; Type: N/A; Interventions: N/A | Arm Label: Gestational Diabetes Mellitus Cohort; Type: N/A; Interventions: N/A | Arm Label: Fresh Milk Cohort; Type: N/A; Interventions: N/A | Arm Label: RNA Milk Fat Cohort; Type: N/A; Interventions: N/A | Arm Label: Skin Study; Type: N/A; Interventions: N/A | Arm Label: BMMI Project; Type: N/A; Interventions: N/A
B: Arm Label: probiotics group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: probiotics | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: glucose solution | Intervention Type: DIETARY_SUPPLEMENT; Name: probiotics; Assigned to Arm(s): probiotics group | Intervention Type: DIETARY_SUPPLEMENT; Name: glucose solution; Assigned to Arm(s): control group
C: Arm Label: Experimental Formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: HMO supplement | Arm Label: Control Formula; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo comparator | Intervention Type: DIETARY_SUPPLEMENT; Name: HMO supplement; Assigned to Arm(s): Experimental Formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo comparator; Assigned to Arm(s): Control Formula
D: Arm Label: "Milk" containing B. Lactis; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotic supplementation | Arm Label: "Milk" containing placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Milk containing placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotic supplementation; Assigned to Arm(s): "Milk" containing B. Lactis | Intervention Type: DIETARY_SUPPLEMENT; Name: Milk containing placebo; Assigned to Arm(s): "Milk" containing placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Apatinib Combined Capecitabine Versus Capecitabine Alone for Adjuvant Therapy in Patients After Biliary Carcinoma Surgery: a Prospective Randomized Controlled Study
Brief Summary: It is a prospective,parallel study to investigate the saftety and efficacy of Apatinib combined Capacitabine in the adjuvant treatment of the biliary cancinoma after operation.


Options:
A: Arm Label: Cisplatin plus Gemcitabine; Type: EXPERIMENTAL; Interventions: Drug: Cisplatin and Gemcitabine | Intervention Type: DRUG; Name: Cisplatin and Gemcitabine; Assigned to Arm(s): Cisplatin plus Gemcitabine
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Radiation: Concurrent Chemoradiotherapy, Drug: capecitabine, Drug: gemcitabine | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: capecitabine, Drug: gemcitabine | Intervention Type: RADIATION; Name: Concurrent Chemoradiotherapy; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: capecitabine; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: gemcitabine; Assigned to Arm(s): Arm 1, Arm 2
C: Arm Label: Test Group; Type: EXPERIMENTAL; Interventions: Drug: Capecitabine, Drug: Apatinib | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Control Group, Test Group | Intervention Type: DRUG; Name: Apatinib; Assigned to Arm(s): Test Group
D: Arm Label: Gemcitabine plus Cisplatin; Type: EXPERIMENTAL; Interventions: Drug: Gemcitabine, Drug: Cisplatin | Arm Label: Capecitabine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Gemcitabine plus Cisplatin | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Gemcitabine plus Cisplatin | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Capecitabine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Safety and Efficacy of Tisagenlecleucel in Pediatric Subjects With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma (NHL)
Brief Summary: The purpose of the study was to assess the efficacy and safety of tisagenlecleucel in pediatric, adolescent and young adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) including Burkitt Lymphoma and Burkitt Leukemia.

For pediatric patients who have r/r B-NHL including Burkitt Lymphoma and Burkitt Leukemia, survival rates are dismal, only \~20-50% subjects are alive at 2 years with overall response rate (ORR) of 20-30% after conventional salvage chemotherapy.


Options:
A: Arm Label: Tisagenlecleucel; Type: EXPERIMENTAL; Interventions: Biological: Tisagenlecleucel, Drug: lymphodepleting chemotherapy, Drug: Bridging Therapy | Intervention Type: BIOLOGICAL; Name: Tisagenlecleucel; Assigned to Arm(s): Tisagenlecleucel | Intervention Type: DRUG; Name: lymphodepleting chemotherapy; Assigned to Arm(s): Tisagenlecleucel | Intervention Type: DRUG; Name: Bridging Therapy; Assigned to Arm(s): Tisagenlecleucel
B: Arm Label: CD19-CART01; Type: EXPERIMENTAL; Interventions: Biological: CD19-CAR T cell | Intervention Type: BIOLOGICAL; Name: CD19-CAR T cell; Assigned to Arm(s): CD19-CART01
C: Arm Label: HIGH DOSE CHEMOTHERAPY AND ASCT; Type: EXPERIMENTAL; Interventions: Drug: Carmustine, Drug: Etoposide, Drug: Cytarabine, Drug: Melphalan, Biological: Pegfilgrastim, Biological: 19-28z T CELLS, Procedure: Autologous Stem Cell Transplantation | Intervention Type: DRUG; Name: Carmustine; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT | Intervention Type: DRUG; Name: Cytarabine; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT | Intervention Type: BIOLOGICAL; Name: Pegfilgrastim; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT | Intervention Type: BIOLOGICAL; Name: 19-28z T CELLS; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT | Intervention Type: PROCEDURE; Name: Autologous Stem Cell Transplantation; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT
D: Arm Label: Treatment (fludarabine, cyclophosphamide, CD19 T cell); Type: EXPERIMENTAL; Interventions: Biological: Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells, Drug: Cyclophosphamide, Drug: Fludarabine | Intervention Type: BIOLOGICAL; Name: Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells; Assigned to Arm(s): Treatment (fludarabine, cyclophosphamide, CD19 T cell) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Treatment (fludarabine, cyclophosphamide, CD19 T cell) | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): Treatment (fludarabine, cyclophosphamide, CD19 T cell)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Community I-STAR Mozambique: Community Implementation of SBIRT Using Technology for Alcohol Use Reduction in Mozambique
Brief Summary: Hazardous drinking (HD) is a major public health burden worldwide with significant morbidity and mortality. To reduce HD, the World Health Organization (WHO) recommends using Screening, Brief Intervention, Referral to Treatment (SBIRT). Mobile health technology (mHealth), such as the mSBIRT app, is a promising tool for widespread cost-effective delivery of evidence-based HDS by community health workers (CHWs) because of its potential to increase fidelity, effectiveness, and sustainability. Community I-STAR Mozambique comprises three phases: 1) mSBIRT adaptation, 2) a cluster-randomized trial, and 3) scale-up of the most cost-effective intervention. Community I-STAR Mozambique will scale-up a cost effective, sustainable program and inform policy applicable to Mozambique and other LMICs.


Options:
A: Arm Label: mSBIRT; Type: EXPERIMENTAL; Interventions: Behavioral: Screening, Brief Intervention, Referral to Treatment | Arm Label: SBIRT-CTS),; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Screening, Brief Intervention, Referral to Treatment | Intervention Type: BEHAVIORAL; Name: Screening, Brief Intervention, Referral to Treatment; Assigned to Arm(s): SBIRT-CTS),, mSBIRT
B: Arm Label: Intervention (iMBC/ECD + C-PrES); Type: EXPERIMENTAL; Interventions: Behavioral: Integrated Mothers and Babies Course | Arm Label: Control (C-PrES); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Integrated Mothers and Babies Course; Assigned to Arm(s): Intervention (iMBC/ECD + C-PrES)
C: Arm Label: REACH-VN; Type: EXPERIMENTAL; Interventions: Behavioral: REACH-VIETNAM | Arm Label: Enhanced control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: REACH-VIETNAM; Assigned to Arm(s): REACH-VN
D: Arm Label: Self Help Plus; Type: EXPERIMENTAL; Interventions: Behavioral: Self Help Plus | Arm Label: Enhanced Treatment As Usual; Type: OTHER; Interventions: Other: Enhanced Treatment As Usual | Intervention Type: BEHAVIORAL; Name: Self Help Plus; Assigned to Arm(s): Self Help Plus | Intervention Type: OTHER; Name: Enhanced Treatment As Usual; Assigned to Arm(s): Enhanced Treatment As Usual

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study With Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis
Brief Summary: The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.


Options:
A: Arm Label: Group 1 (Guselkumab: Placebo); Type: EXPERIMENTAL; Interventions: Drug: Guselkumab, Drug: Placebo | Arm Label: Group 2 (Placebo: Guselkumab); Type: EXPERIMENTAL; Interventions: Drug: Guselkumab, Drug: Placebo | Intervention Type: DRUG; Name: Guselkumab; Assigned to Arm(s): Group 1 (Guselkumab: Placebo), Group 2 (Placebo: Guselkumab) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1 (Guselkumab: Placebo), Group 2 (Placebo: Guselkumab)
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Secukinumab 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 150mg | Arm Label: Secukinumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 300mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Secukinumab 150mg; Assigned to Arm(s): Secukinumab 150 mg | Intervention Type: DRUG; Name: Secukinumab 300mg; Assigned to Arm(s): Secukinumab 300 mg
C: Arm Label: BMS-986165; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Active comparator; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apremilast | Intervention Type: DRUG; Name: BMS-986165; Assigned to Arm(s): BMS-986165 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Active comparator
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Bimekizumab dosing regimen 1; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Bimekizumab dosing regimen 2; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Bimekizumab dosing regimen 3; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Bimekizumab dosing regimen 4; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Bimekizumab dosing regimen 5; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab | Intervention Type: DRUG; Name: Bimekizumab; Assigned to Arm(s): Bimekizumab dosing regimen 1, Bimekizumab dosing regimen 2, Bimekizumab dosing regimen 3, Bimekizumab dosing regimen 4, Bimekizumab dosing regimen 5 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Bimekizumab dosing regimen 1, Bimekizumab dosing regimen 2, Bimekizumab dosing regimen 3, Bimekizumab dosing regimen 4, Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomized Controlled Trial Comparing Different Needles for Oocyte's Retrieval.
Brief Summary: In the early stages of assisted reproductive technologies (ART), oocyte retrieval was performed via laparoscopy, a cumbersome and expensive process requiring general anesthesia. Today, transvaginal oocyte retrieval for ART is a routine procedure performed under ultrasound guidance. Double-lumen retrieval needles, which are capable of flushing ovarian follicles, were developed to overcome the possibility of oocyte retention within the ovarian follicles and retrieval collection system. Single lumen needles have been introduced and are routinely used by most groups due to their supposed ability to retrieve the same number of oocytes in a shorter operation time.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Patients receiving short protocol IVF/ICSI-treatment. | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Long protocol | Intervention Type: DRUG; Name: Patients receiving short protocol IVF/ICSI-treatment.; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Long protocol; Assigned to Arm(s): 2
B: Arm Label: follicular flushing group; Type: EXPERIMENTAL; Interventions: Other: follicular flushing | Arm Label: aspiration group; Type: ACTIVE_COMPARATOR; Interventions: Other: no follicular flushing | Intervention Type: OTHER; Name: follicular flushing; Assigned to Arm(s): follicular flushing group | Intervention Type: OTHER; Name: no follicular flushing; Assigned to Arm(s): aspiration group
C: Arm Label: SL1(Cook® Single Lumen); Type: ACTIVE_COMPARATOR; Interventions: Device: Oocyte retrieval with only aspiration system "SL1(Cook® Single Lumen)" | Arm Label: DL1 (Cook® EchoTip® Double Lumen); Type: ACTIVE_COMPARATOR; Interventions: Device: Oocyte retrieval with aspiration and flushing system "DL1 (Cook® EchoTip® Double Lumen)" | Intervention Type: DEVICE; Name: Oocyte retrieval with only aspiration system "SL1(Cook® Single Lumen)"; Assigned to Arm(s): SL1(Cook® Single Lumen) | Intervention Type: DEVICE; Name: Oocyte retrieval with aspiration and flushing system "DL1 (Cook® EchoTip® Double Lumen)"; Assigned to Arm(s): DL1 (Cook® EchoTip® Double Lumen)
D: Arm Label: Follicular flushing; Type: ACTIVE_COMPARATOR; Interventions: Other: Aspiration without flushing follicles with culture media, Other: Follicular Flushing | Intervention Type: OTHER; Name: Aspiration without flushing follicles with culture media; Assigned to Arm(s): Follicular flushing | Intervention Type: OTHER; Name: Follicular Flushing; Assigned to Arm(s): Follicular flushing

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An mHealth, Multi-Centre Randomized Controlled Trial to Promote Use of Postpartum Contraception Amongst Rural Women in Punjab, Pakistan
Brief Summary: Multiple encounters of pregnant women with the health care system during the late antenatal and immediate postpartum period provide a gateway for postpartum family planning counselling. Counselling on family planning services during this time is considered effective and cost-efficient for promoting healthy timing and spacing of pregnancies. This research aims to test the effectiveness of mobile phone-based interventions in promoting use of postpartum contraception.


Options:
A: Arm Label: Basic Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Basic Treatment | Arm Label: Interactive Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Interactive Treatment | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Other: Control, comparator arm | Intervention Type: BEHAVIORAL; Name: Interactive Treatment; Assigned to Arm(s): Interactive Treatment | Intervention Type: BEHAVIORAL; Name: Basic Treatment; Assigned to Arm(s): Basic Treatment | Intervention Type: OTHER; Name: Control, comparator arm; Assigned to Arm(s): Control
B: Arm Label: Text Messaging Intervention; Type: EXPERIMENTAL; Interventions: Other: Text Messaging Intervention | Arm Label: Standard Referral; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Referral | Intervention Type: OTHER; Name: Text Messaging Intervention; Assigned to Arm(s): Text Messaging Intervention | Intervention Type: OTHER; Name: Standard Referral; Assigned to Arm(s): Standard Referral
C: Arm Label: Two-way SMS; Type: EXPERIMENTAL; Interventions: Behavioral: Two-way SMS | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Two-way SMS; Assigned to Arm(s): Two-way SMS
D: Arm Label: Text and Voice Messages; Type: EXPERIMENTAL; Interventions: Behavioral: Text and Voice Messages | Arm Label: Interactive Phone Call; Type: EXPERIMENTAL; Interventions: Behavioral: Interactive Phone Call | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Text and Voice Messages; Assigned to Arm(s): Text and Voice Messages | Intervention Type: BEHAVIORAL; Name: Interactive Phone Call; Assigned to Arm(s): Interactive Phone Call

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An mHealth, Multi-Centre Randomized Controlled Trial to Promote Use of Postpartum Contraception Amongst Rural Women in Punjab, Pakistan
Brief Summary: Multiple encounters of pregnant women with the health care system during the late antenatal and immediate postpartum period provide a gateway for postpartum family planning counselling. Counselling on family planning services during this time is considered effective and cost-efficient for promoting healthy timing and spacing of pregnancies. This research aims to test the effectiveness of mobile phone-based interventions in promoting use of postpartum contraception.


Options:
A: Arm Label: Phone counseling intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-delivered mobile phone counseling intervention, Behavioral: Treatment as Usual | Arm Label: Treatment as Usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as Usual | Intervention Type: BEHAVIORAL; Name: Nurse-delivered mobile phone counseling intervention; Assigned to Arm(s): Phone counseling intervention | Intervention Type: BEHAVIORAL; Name: Treatment as Usual; Assigned to Arm(s): Phone counseling intervention, Treatment as Usual
B: Intervention Type: BEHAVIORAL; Name: Pulse; Assigned to Arm(s): N/A
C: Arm Label: Text and Voice Messages; Type: EXPERIMENTAL; Interventions: Behavioral: Text and Voice Messages | Arm Label: Interactive Phone Call; Type: EXPERIMENTAL; Interventions: Behavioral: Interactive Phone Call | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Text and Voice Messages; Assigned to Arm(s): Text and Voice Messages | Intervention Type: BEHAVIORAL; Name: Interactive Phone Call; Assigned to Arm(s): Interactive Phone Call
D: Arm Label: Crowdsourced intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Crowdsourced materials | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: BEHAVIORAL; Name: Crowdsourced materials; Assigned to Arm(s): Crowdsourced intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control

Answer: C